Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience Thursday morning reported a 3 percent uptick in fiscal second quarter revenues bolstered by growth in its Diagnostics segment and particularly sales of its Illumigene product line.

For the three months ended March 31, the Cincinnati-based diagnostics and life science research tools firm reported revenues of $51.5 million compared to $50.1 million in fiscal Q2 2014, and beating analysts' consensus estimate of $50.4 million. On a currency-neutral basis, revenues increased 6 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.